The Inotuzumab Ozogamicin Market is expected to register at a signifcant CAGR during the forecast period. Inotuzumab Ozogamicin is an antibody-drug conjugate that uses the same linker and cytotoxic chemical technology as Mylotarg (Gemtuzumabozogamicin), which was authorised by the US FDA in 2000, for the treatment of acute myeloid leukaemia.

The market for Inotuzumab Ozogamicin is likely to grow as about 10% to 20% of patients who have achieved complete remission following first treatment for ALL (acute lymphoblastic leukemia) are expected to recur. The relapse rate in children is around 10%, whereas the relapse rate in adults is closer to 50%. ALL relapses usually happen within two years of starting treatment; however, it can happen months or years after the original remission.

The revenue share of the Inotuzumab Ozogamicin market will increase as the healthcare industry develops. The market will expand as people are becoming more aware of health issues, and better facilities are being available. As a result, the market in developed regions will grow dramatically.

The World Health Organization has declared Inotuzumab Ozogamicin,a public health emergency after the COVID-19 virus outbreak in December 2019. The disease has spread to over 100 nations and resulted in massive deaths all across the globe. Global manufacturing, tourism, and financial sectors have all been heavily damaged.

The high rate of relapse owing to acute lymphoblastic leukaemia in both children and adults is one of the factors driving the Inotuzumab Ozogamicin market. It is critical to raise awareness about the illness and get a timely diagnosis so that it can be treated.

In 2019, the Korean government announced that Besponsa (Inotuzumab ozogamicin) will be covered by insurance because alternative medicines are much more expensive than reimbursing the cost of Besponsa.

In 2017, The European Commission authorized Inotuzumab Ozogamicin for the treatment of people with elapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL). 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Regions Covered- Globally
• Competitive Landscape: Pfizer

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Inotuzumab Ozogamicin Market Segmentation by product type: 

o 0.9mg

o 1.0mg

Inotuzumab Ozogamicin Market Segmentation by application: 

o Hospital

o Pharmacy

Inotuzumab Ozogamicin Market by Region